Identification of emerging FLT3 ITD-positive clones during clinical remission and kinetics of disease relapse in acute myeloid leukaemia with mutated nucleophosmin

Tiziana Ottone, Serena Zaza, Mariadomenica Divona, Syed Khizer Hasan, Serena Lavorgna, Serena Laterza, Laura Cicconi, Paola Panetta, Jonny Di Giandomenico, Michela Cittadini, Claudia Ciardi, Enrico Montefusco, Annibale Franchi, Luciana Annino, Adriano Venditti, Sergio Amadori, Francesco Lo-Coco

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

FLT3 internal tandem duplication (ITD) mutations are frequently detected at diagnosis in cytogenetically normal acute myeloid leukaemia (CN-AML) and predict unfavourable outcome. FLT3 ITD is an unstable aberration and may be lost or acquired at relapse. Recent whole genome sequencing studies have suggested that FLT3 ITD+ve AML relapse may evolve from small subclones undetectable at diagnosis by routine polymerase chain reaction (PCR). We developed a patient-specific real-time quantitative-PCR (RQ-PCR) to implement FLT3 ITD detection in six AML patients whose blasts carried wild-type FLT3 at diagnosis and who relapsed with FLT3 ITD by routine PCR. Patient-specific forward primers were designed after cloning and sequencing the FLT3 ITD in each case. The assay allowed retrospective detection of FLT3 ITD in diagnostic samples of 4/6 cases and to establish the kinetics of clonal evolution preceding relapse. After conventional chemotherapy, all patients had early relapse despite having been classified as NPM1+ve/FLT3 ITD-ve at presentation, with shorter remissions being observed in four patients re-classified as FLT3 ITD+ve by the new assay. Notably, FLT3 ITD clone became detectable by conventional PCR in three patients tested during remission after initial treatment. Our data underscore the need of identifying low FLT3 ITD levels, which are probably associated with relapse in otherwise good prognosis CN-AML.

Original languageEnglish
Pages (from-to)533-540
Number of pages8
JournalBritish Journal of Haematology
Volume161
Issue number4
DOIs
Publication statusPublished - May 2013

Fingerprint

Acute Myeloid Leukemia
Clone Cells
Recurrence
Polymerase Chain Reaction
Clonal Evolution
nucleophosmin
Organism Cloning
Real-Time Polymerase Chain Reaction
Genome
Drug Therapy
Mutation

Keywords

  • AML
  • FLT3 ITD
  • NPM1
  • Patient-specific RQ-PCR
  • Relapse

ASJC Scopus subject areas

  • Hematology

Cite this

Identification of emerging FLT3 ITD-positive clones during clinical remission and kinetics of disease relapse in acute myeloid leukaemia with mutated nucleophosmin. / Ottone, Tiziana; Zaza, Serena; Divona, Mariadomenica; Hasan, Syed Khizer; Lavorgna, Serena; Laterza, Serena; Cicconi, Laura; Panetta, Paola; Giandomenico, Jonny Di; Cittadini, Michela; Ciardi, Claudia; Montefusco, Enrico; Franchi, Annibale; Annino, Luciana; Venditti, Adriano; Amadori, Sergio; Lo-Coco, Francesco.

In: British Journal of Haematology, Vol. 161, No. 4, 05.2013, p. 533-540.

Research output: Contribution to journalArticle

Ottone, T, Zaza, S, Divona, M, Hasan, SK, Lavorgna, S, Laterza, S, Cicconi, L, Panetta, P, Giandomenico, JD, Cittadini, M, Ciardi, C, Montefusco, E, Franchi, A, Annino, L, Venditti, A, Amadori, S & Lo-Coco, F 2013, 'Identification of emerging FLT3 ITD-positive clones during clinical remission and kinetics of disease relapse in acute myeloid leukaemia with mutated nucleophosmin', British Journal of Haematology, vol. 161, no. 4, pp. 533-540. https://doi.org/10.1111/bjh.12288
Ottone, Tiziana ; Zaza, Serena ; Divona, Mariadomenica ; Hasan, Syed Khizer ; Lavorgna, Serena ; Laterza, Serena ; Cicconi, Laura ; Panetta, Paola ; Giandomenico, Jonny Di ; Cittadini, Michela ; Ciardi, Claudia ; Montefusco, Enrico ; Franchi, Annibale ; Annino, Luciana ; Venditti, Adriano ; Amadori, Sergio ; Lo-Coco, Francesco. / Identification of emerging FLT3 ITD-positive clones during clinical remission and kinetics of disease relapse in acute myeloid leukaemia with mutated nucleophosmin. In: British Journal of Haematology. 2013 ; Vol. 161, No. 4. pp. 533-540.
@article{232c46ea019e45b4a01022fb6ddb0ae5,
title = "Identification of emerging FLT3 ITD-positive clones during clinical remission and kinetics of disease relapse in acute myeloid leukaemia with mutated nucleophosmin",
abstract = "FLT3 internal tandem duplication (ITD) mutations are frequently detected at diagnosis in cytogenetically normal acute myeloid leukaemia (CN-AML) and predict unfavourable outcome. FLT3 ITD is an unstable aberration and may be lost or acquired at relapse. Recent whole genome sequencing studies have suggested that FLT3 ITD+ve AML relapse may evolve from small subclones undetectable at diagnosis by routine polymerase chain reaction (PCR). We developed a patient-specific real-time quantitative-PCR (RQ-PCR) to implement FLT3 ITD detection in six AML patients whose blasts carried wild-type FLT3 at diagnosis and who relapsed with FLT3 ITD by routine PCR. Patient-specific forward primers were designed after cloning and sequencing the FLT3 ITD in each case. The assay allowed retrospective detection of FLT3 ITD in diagnostic samples of 4/6 cases and to establish the kinetics of clonal evolution preceding relapse. After conventional chemotherapy, all patients had early relapse despite having been classified as NPM1+ve/FLT3 ITD-ve at presentation, with shorter remissions being observed in four patients re-classified as FLT3 ITD+ve by the new assay. Notably, FLT3 ITD clone became detectable by conventional PCR in three patients tested during remission after initial treatment. Our data underscore the need of identifying low FLT3 ITD levels, which are probably associated with relapse in otherwise good prognosis CN-AML.",
keywords = "AML, FLT3 ITD, NPM1, Patient-specific RQ-PCR, Relapse",
author = "Tiziana Ottone and Serena Zaza and Mariadomenica Divona and Hasan, {Syed Khizer} and Serena Lavorgna and Serena Laterza and Laura Cicconi and Paola Panetta and Giandomenico, {Jonny Di} and Michela Cittadini and Claudia Ciardi and Enrico Montefusco and Annibale Franchi and Luciana Annino and Adriano Venditti and Sergio Amadori and Francesco Lo-Coco",
year = "2013",
month = "5",
doi = "10.1111/bjh.12288",
language = "English",
volume = "161",
pages = "533--540",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "John Wiley & Sons, Ltd (10.1111)",
number = "4",

}

TY - JOUR

T1 - Identification of emerging FLT3 ITD-positive clones during clinical remission and kinetics of disease relapse in acute myeloid leukaemia with mutated nucleophosmin

AU - Ottone, Tiziana

AU - Zaza, Serena

AU - Divona, Mariadomenica

AU - Hasan, Syed Khizer

AU - Lavorgna, Serena

AU - Laterza, Serena

AU - Cicconi, Laura

AU - Panetta, Paola

AU - Giandomenico, Jonny Di

AU - Cittadini, Michela

AU - Ciardi, Claudia

AU - Montefusco, Enrico

AU - Franchi, Annibale

AU - Annino, Luciana

AU - Venditti, Adriano

AU - Amadori, Sergio

AU - Lo-Coco, Francesco

PY - 2013/5

Y1 - 2013/5

N2 - FLT3 internal tandem duplication (ITD) mutations are frequently detected at diagnosis in cytogenetically normal acute myeloid leukaemia (CN-AML) and predict unfavourable outcome. FLT3 ITD is an unstable aberration and may be lost or acquired at relapse. Recent whole genome sequencing studies have suggested that FLT3 ITD+ve AML relapse may evolve from small subclones undetectable at diagnosis by routine polymerase chain reaction (PCR). We developed a patient-specific real-time quantitative-PCR (RQ-PCR) to implement FLT3 ITD detection in six AML patients whose blasts carried wild-type FLT3 at diagnosis and who relapsed with FLT3 ITD by routine PCR. Patient-specific forward primers were designed after cloning and sequencing the FLT3 ITD in each case. The assay allowed retrospective detection of FLT3 ITD in diagnostic samples of 4/6 cases and to establish the kinetics of clonal evolution preceding relapse. After conventional chemotherapy, all patients had early relapse despite having been classified as NPM1+ve/FLT3 ITD-ve at presentation, with shorter remissions being observed in four patients re-classified as FLT3 ITD+ve by the new assay. Notably, FLT3 ITD clone became detectable by conventional PCR in three patients tested during remission after initial treatment. Our data underscore the need of identifying low FLT3 ITD levels, which are probably associated with relapse in otherwise good prognosis CN-AML.

AB - FLT3 internal tandem duplication (ITD) mutations are frequently detected at diagnosis in cytogenetically normal acute myeloid leukaemia (CN-AML) and predict unfavourable outcome. FLT3 ITD is an unstable aberration and may be lost or acquired at relapse. Recent whole genome sequencing studies have suggested that FLT3 ITD+ve AML relapse may evolve from small subclones undetectable at diagnosis by routine polymerase chain reaction (PCR). We developed a patient-specific real-time quantitative-PCR (RQ-PCR) to implement FLT3 ITD detection in six AML patients whose blasts carried wild-type FLT3 at diagnosis and who relapsed with FLT3 ITD by routine PCR. Patient-specific forward primers were designed after cloning and sequencing the FLT3 ITD in each case. The assay allowed retrospective detection of FLT3 ITD in diagnostic samples of 4/6 cases and to establish the kinetics of clonal evolution preceding relapse. After conventional chemotherapy, all patients had early relapse despite having been classified as NPM1+ve/FLT3 ITD-ve at presentation, with shorter remissions being observed in four patients re-classified as FLT3 ITD+ve by the new assay. Notably, FLT3 ITD clone became detectable by conventional PCR in three patients tested during remission after initial treatment. Our data underscore the need of identifying low FLT3 ITD levels, which are probably associated with relapse in otherwise good prognosis CN-AML.

KW - AML

KW - FLT3 ITD

KW - NPM1

KW - Patient-specific RQ-PCR

KW - Relapse

UR - http://www.scopus.com/inward/record.url?scp=84876798097&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876798097&partnerID=8YFLogxK

U2 - 10.1111/bjh.12288

DO - 10.1111/bjh.12288

M3 - Article

C2 - 23480665

AN - SCOPUS:84876798097

VL - 161

SP - 533

EP - 540

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 4

ER -